Sarepta Therapeutics ( NASDAQ:SRPT – Get Rating ) had its price objective increased by Credit Suisse Group from $137.00 to $144.00 in a report issued on Wednesday morning, The Fly reports. The brokerage currently has a neutral rating on the biotechnology company's stock. Other equities research analysts have also recently issued reports about the company. Cantor Fitzgerald lifted their price objective on Sarepta Therapeutics from $150.00 to $174.00 in a research note on Tuesday, December 13th.

https://www.dailypolitical.com/2023/03/05/sarepta-therapeutics-nasdaqsrpt-given-new-144-00-price-target-at-credit-suisse-group.html

#dailypolitical